An investigation on behalf of investors of Dr. Reddys Laboratories Limited (NYSE: RDY) shares over potential securities laws violations by Dr. Reddys Laboratories and certain of its directors and officers in connection with certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Dr. Reddys Laboratories Limited (NYSE: RDY) concerning whether a series of statements by Dr. Reddys Laboratories regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On June 15, 2018, the U.S. District Court for the District of New Jersey granted a request by Indivior PLC (Indivior) for a temporary restraining order compelling Dr. Reddy's Laboratories Limiteds to cease its launch activities related to the Companys Suboxone Film product, pending resolution of Indiviors motion for a preliminary injunction to block the products release.

On July 13, 2018, the court granted Indiviors motion and entered a preliminary injunction order to that effect.

Dr. Reddy's Laboratories Limited (NYSE: RDY) closed on July 26, 2018, at $31.20 per share.